NEW YORK (360Dx) – Genfit, one of several companies vying to develop a cure for the increasingly prevalent chronic liver disease nonalcoholic steatohepatitis (NASH), said it has successfully completed the feasibility stage in the development of its biomarker-based in vitro diagnostic for the condition.

If proven clinically useful, the noninvasive blood-based test could represent a significant improvement in the diagnosis of NASH, which can currently be definitively diagnosed only through liver biopsy.